Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease.
Agostinelli, C., Gallamini, A., Stracqualursi, L., Agati, P., Tripodo, C., Fuligni, F., et al. (2016). The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study. THE LANCET. HAEMATOLOGY, 3(10), e467-e479 [10.1016/S2352-3026(16)30108-9].
The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study
TRIPODO, Claudio;
2016-01-01
Abstract
Early-interim fluorodeoxyglucose (FDG)-PET scan after two ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy courses (PET-2) represents the most effective predictor of treatment outcome in classical Hodgkin's lymphoma. We aimed to assess the predictive value of PET-2 combined with tissue biomarkers in neoplastic and microenvironmental cells for this disease.
| File | Dimensione | Formato | |
|---|---|---|---|
|
1-s2.0-S2352302616301089.pdf
Solo gestori archvio
Dimensione
3.27 MB
Formato
Adobe PDF
|
3.27 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
